Background and purposeAccurate estimation of Overall Survival (OS) in Non-Small Cell Lung Cancer (NSCLC) patients provides critical insights for treatment planning. While previous studies showed that radiomics and Deep Learning (DL) features increased prediction accuracy, this study aimed to examine whether a model that combines the radiomics and DL features with the clinical and dosimetric features outperformed other models. Materials and methodsWe collected pre-treatment lung CT scans and clinical data for 225 NSCLC patients from the Maastro Clinic: 180 for training and 45 for testing. Radiomics features were extracted using the Python radiomics feature extractor, and DL features were obtained using a 3D ResNet model. An ensemble model comprising XGB and NN classifiers was developed using: (1) clinical features only; (2) clinical and radiomics features; (3) clinical and DL features; and (4) clinical, radiomics, and DL features. The performance metrics were evaluated for the test and K-fold cross-validation data sets. ResultsThe prediction model utilizing only clinical variables provided an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.64 and a test accuracy of 77.55%. The best performance came from combining clinical, radiomics, and DL features (AUC: 0.84, accuracy: 85.71%). The prediction improvement of this model was statistically significant compared to models trained with clinical features alone or with a combination of clinical and radiomics features. ConclusionIntegrating radiomics and DL features with clinical characteristics improved the prediction of OS after radiotherapy for NSCLC patients. The increased accuracy of our integrated model enables personalized, risk-based treatment planning, guiding clinicians toward more effective interventions, improved patient outcomes and enhanced quality of life.

BackgroundGadolinium-based Contrast Agents (GBCAs) are used in brain MRI exams to improve the visualization of pathology and improve the delineation of lesions. Higher doses of GBCAs can improve lesion sensitivity but involve substantial deviation from standard-of-care procedures and may have safety implications, particularly in the light of recent findings on gadolinium retention and deposition. PurposeTo evaluate the clinical performance of an FDA cleared deep-learning (DL) based contrast boosting algorithm in routine clinical brain MRI exams. MethodsA multi-center retrospective database of contrast-enhanced brain MRI images (obtained from April 2017 to December 2023) was used to evaluate a DL-based contrast boosting algorithm. Pre-contrast and standard post-contrast (SC) images were processed with the algorithm to obtain contrast boosted (CB) images. Quantitative performance of CB images in comparison to SC images was compared using contrast-to-noise ratio (CNR), lesion-to-brain ratio (LBR) and contrast enhancement percentage (CEP). Three board-certified radiologists reviewed CB and SC images side-by-side for qualitative evaluation and rated them on a 4-point Likert scale for lesion contrast enhancement, border delineation, internal morphology, overall image quality, presence of artefacts, and changes in vessel conspicuity. The presence, cause, and severity of any false lesions was recorded. CB results were compared to SC using Wilcoxon signed rank test for statistical significance. ResultsBrain MRI images from 110 patients (47 {+/-} 22 years; 52 Females, 47 Males, 11 N/A) were evaluated. CB images had superior quantitative performance than SC images in terms of CNR (+634%), LBR (+70%) and CEP (+150%). In the qualitative assessment CB images showed better lesion visualization (3.73 vs 3.16) and had better image quality (3.55 vs 3.07). Readers were able to rule out all false lesions on CB by using SC for comparison. ConclusionsDeep learning based contrast boosting improves lesion visualization and image quality without increasing contrast dosage. Key ResultsO_LIIn a retrospective study of 110 patients, deep-learning based contrast boosted (CB) images showed better lesion visualization than standard post-contrast (SC) brain MRI images (3.73 vs 3.16; mean reader scores [4-point Likert scale]) C_LIO_LICB images had better overall image quality than SC images (3.55 vs 3.07) C_LIO_LIContrast-to-noise ratio, Lesion-to-brain Ratio and Contrast Enhancement Percentage for CB images were significantly higher than SC images (+729%, +88% and +165%; p < 0.001) C_LI Summary StatementDeep-learning based contrast boosting achieves better lesion visualization and overall image quality and provides more contrast information, without increasing the contrast dosage in contrast-enhanced brain MR protocols.

IntroductionIntegrated digital diagnostics can support complex surgeries in many anatomic sites, and brain tumour surgery represents one of the most complex cases. Neurosurgeons face several challenges during brain tumour surgeries, such as differentiating critical tissue from brain tumour margins. To overcome these challenges, the STRATUM project will develop a 3D decision support tool for brain surgery guidance and diagnostics based on multimodal data processing, including hyperspectral imaging, integrated as a point-of-care computing tool in neurosurgical workflows. This paper reports the protocol for the development and technical validation of the STRATUM tool. Methods and analysisThis international multicentre, prospective, open, observational cohort study, STRATUM-OS (study: 28 months, pre-recruitment: 2 months, recruitment: 20 months, follow-up: 6 months), with no control group, will collect data from 320 patients undergoing standard neurosurgical procedures to: (1) develop and technically validate the STRATUM tool, and (2) collect the outcome measures for comparing the standard procedure versus the standard procedure plus the use of the STRATUM tool during surgery in a subsequent historically controlled non-randomized clinical trial. Ethics and disseminationThe protocol was approved by the participant Ethics Committees. Results will be disseminated in scientific conferences and peer-reviewed journals. Trial registration number[Pending Number] ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LISTRATUM-OS will be the first multicentre prospective observational study to develop and technically validate a 3D decision support tool for brain surgery guidance and diagnostics in real-time based on artificial intelligence and multimodal data processing, including the emerging hyperspectral imaging modality. C_LIO_LIThis study encompasses a prospective collection of multimodal pre, intra and postoperative medical data, including innovative imaging modalities, from patients with intra-axial brain tumours. C_LIO_LIThis large observational study will act as historical control in a subsequent clinical trial to evaluate a fully-working prototype. C_LIO_LIAlthough the estimated sample size is deemed adequate for the purpose of the study, the complexity of the clinical context and the type of surgery could potentially lead to under-recruitment and under-representation of less prevalent tumour types. C_LI

Despite the advances in automated medical image segmentation, AI models still underperform in various clinical settings, challenging real-world integration. In this multicenter evaluation, we analyzed 20 state-of-the-art mandibular segmentation models across 19,218 segmentations of 1,000 clinically resampled CT/CBCT scans. We show that segmentation accuracy varies by up to 25% depending on socio-technical factors such as voxel size, bone orientation, and patient conditions such as osteosynthesis or pathology. Higher sharpness, isotropic smaller voxels, and neutral orientation significantly improved results, while metallic osteosynthesis and anatomical complexity led to significant degradation. Our findings challenge the common view of AI models as "plug-and-play" tools and suggest evidence-based optimization recommendations for both clinicians and developers. This will in turn boost the integration of AI segmentation tools in routine healthcare.

BackgroundIntracranial hemorrhage (ICH), whether spontaneous or traumatic, is a neurological emergency with high morbidity and mortality. Accurate assessment of severity is essential for neurosurgical decision-making. This study aimed to develop and evaluate a fully automated, deep learning-based tool for the standardized assessment of ICH severity, based on the segmentation of the hemorrhage and intracranial structures, and the computation of an objective severity index. MethodsNon-contrast cranial CT scans from patients with spontaneous or traumatic ICH were retrospectively collected from public datasets and a tertiary care center. Deep learning models were trained to segment hemorrhages and intracranial structures. These segmentations were used to compute a severity index reflecting bleeding burden and mass effect through volumetric relationships. Segmentation performance was evaluated on a hold-out test cohort. In a prospective cohort, the severity index was assessed in relation to expert-rated CT severity, clinical outcomes, and the need for urgent neurosurgical intervention. ResultsA total of 1,110 non-contrast cranial CT scans were analyzed, 900 from the retrospective cohort and 200 from the prospective evaluation cohort. The binary segmentation model achieved a median Dice score of 0.90 for total hemorrhage. The multilabel model yielded Dice scores ranging from 0.55 to 0.94 across hemorrhage subtypes. The severity index significantly correlated with expert-rated CT severity (p < 0.001), the modified Rankin Scale (p = 0.007), and the Glasgow Outcome Scale-Extended (p = 0.039), and independently predicted the need for urgent surgery (p < 0.001). A threshold [~]300 was identified as a decision point for surgical management (AUC = 0.83). ConclusionWe developed a fully automated and openly accessible pipeline for the analysis of non-contrast cranial CT in intracranial hemorrhage. It computes a novel index that objectively quantifies hemorrhage severity and is significantly associated with clinically relevant outcomes, including the need for urgent neurosurgical intervention.

ImportanceUnderstanding the relevance of covert cerebrovascular disease (CCD) for later health will allow clinicians to more effectively monitor and target interventions. ObjectiveTo examine the association between clinically reported CCD, measured using natural language processing (NLP), and subsequent disease risk. Design, Setting and ParticipantsWe conducted a retrospective e-cohort study using linked health record data. From all people with clinical brain imaging in Scotland from 2010 to 2018, we selected people with no prior hospitalisation for neurological disease. The data were analysed from March 2024 to June 2025. ExposureFour phenotypes were identified with NLP of imaging reports: white matter hypoattenuation or hyperintensities (WMH), lacunes, cortical infarcts and cerebral atrophy. Main outcomes and measuresHazard ratios (aHR) for stroke, dementia, and Parkinsons disease (conditions previously associated with CCD), epilepsy (a brain-based control condition) and colorectal cancer (a non-brain control condition), adjusted for age, sex, deprivation, region, scan modality, and pre-scan healthcare, were calculated for each phenotype. ResultsFrom 395,273 people with brain imaging and no history of neurological disease, 145,978 (37%) had [&ge;]1 phenotype. For each phenotype, the aHR of any stroke was: WMH 1.4 (95%CI: 1.3-1.4), lacunes 1.6 (1.5-1.6), cortical infarct 1.7 (1.6-1.8), and cerebral atrophy 1.1 (1.0-1.1). The aHR of any dementia was: WMH, 1.3 (1.3-1.3), lacunes, 1.0 (0.9-1.0), cortical infarct 1.1 (1.0-1.1) and cerebral atrophy 1.7 (1.7-1.7). The aHR of Parkinsons disease was, in people with a report of: WMH 1.1 (1.0-1.2), lacunes 1.1 (0.9-1.2), cortical infarct 0.7 (0.6-0.9) and cerebral atrophy 1.4 (1.3-1.5). The aHRs between CCD phenotypes and epilepsy and colorectal cancer overlapped the null. Conclusions and RelevanceNLP identified CCD and atrophy phenotypes from routine clinical image reports, and these had important associations with future stroke, dementia and Parkinsons disease. Prevention of neurological disease in people with CCD should be a priority for healthcare providers and policymakers. Key PointsO_ST_ABSQuestionC_ST_ABSAre measures of Covert Cerebrovascular Disease (CCD) associated with the risk of subsequent disease (stroke, dementia, Parkinsons disease, epilepsy, and colorectal cancer)? FindingsThis study used a validated NLP algorithm to identify CCD (white matter hypoattenuation/hyperintensities, lacunes, cortical infarcts) and cerebral atrophy from both MRI and computed tomography (CT) imaging reports generated during routine healthcare in >395K people in Scotland. In adjusted models, we demonstrate higher risk of dementia (particularly Alzheimers disease) in people with atrophy, and higher risk of stroke in people with cortical infarcts. However, associations with an age-associated control outcome (colorectal cancer) were neutral, supporting a causal relationship. It also highlights differential associations between cerebral atrophy and dementia and cortical infarcts and stroke risk. MeaningCCD or atrophy on brain imaging reports in routine clinical practice is associated with a higher risk of stroke or dementia. Evidence is needed to support treatment strategies to reduce this risk. NLP can identify these important, otherwise uncoded, disease phenotypes, allowing research at scale into imaging-based biomarkers of dementia and stroke.

Background and AimsRevascularization in stable coronary artery disease often relies on ischemia severity, but we introduce an AI-driven approach that uses clinical and imaging data to estimate individualized treatment effects and guide personalized decisions. MethodsUsing a large, international registry from 13 centers, we developed an AI model to estimate individual treatment effects by simulating outcomes under alternative therapeutic strategies. The model was trained on an internal cohort constructed using 1:1 propensity score matching to emulate randomized controlled trials (RCTs), creating balanced patient pairs in which only the treatment strategy--early revascularization (defined as any procedure within 90 days of MPI) versus medical therapy--differed. This design allowed the model to estimate individualized treatment effects, forming the basis for counterfactual reasoning at the patient level. We then derived the AI-REVASC score, which quantifies the potential benefit, for each patient, of early revascularization. The score was validated in the held-out testing cohort using Cox regression. ResultsOf 45,252 patients, 19,935 (44.1%) were female, median age 65 (IQR: 57-73). During a median follow-up of 3.6 years (IQR: 2.7-4.9), 4,323 (9.6%) experienced MI or death. The AI model identified a group (n=1,335, 5.9%) that benefits from early revascularization with a propensity-adjusted hazard ratio of 0.50 (95% CI: 0.25-1.00). Patients identified for early revascularization had higher prevalence of hypertension, diabetes, dyslipidemia, and lower LVEF. ConclusionsThis study pioneers a scalable, data-driven approach that emulates randomized trials using retrospective data. The AI-REVASC score enables precision revascularization decisions where guidelines and RCTs fall short. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/25329295v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): [email protected]@1df75d8org.highwire.dtl.DTLVardef@1b1ce68org.highwire.dtl.DTLVardef@663cdf_HPS_FORMAT_FIGEXP M_FIG C_FIG

IntroductionAccurately predicting Alzheimers Disease (AD) progression is useful for clinical care. The 2019 TADPOLE (The Alzheimers Disease Prediction Of Longitudinal Evolution) challenge evaluated 92 algorithms from 33 teams worldwide. Unlike typical clinical prediction studies, TADPOLE accommodates (1) variable number of observed timepoints across patients, (2) missing data across modalities and visits, and (3) prediction over an open-ended time horizon, which better reflects real-world data. However, TADPOLE only used the Alzheimers Disease Neuroimaging Initiative (ADNI) dataset, so how well top algorithms generalize to other cohorts remains unclear. MethodsWe tested five algorithms in three external datasets covering 2,312 participants and 13,200 timepoints. The algorithms included FROG, the overall TADPOLE winner, which utilized a unique Longitudinal-to-Cross-sectional (L2C) transformation to convert variable-length longitudinal histories into feature vectors of the same length across participants (i.e., same-length feature vectors). We also considered two FROG variants. One variant unified all XGBoost models from the original FROG with a single feedforward neural network (FNN), which we referred to as L2C-FNN. We also included minimal recurrent neural networks (MinimalRNN), which was ranked second at publication time, as well as AD Course Map (AD-Map), which outperformed MinimalRNN at publication time. All five models - three FROG variants, MinimalRNN and AD-Map - were trained on ADNI and tested on the external datasets. ResultsL2C-FNN performed the best overall. In the case of predicting cognition and ventricle volume, L2C-FNN and AD-Map were the best. For clinical diagnosis prediction, L2C-FNN was the best, while AD-Map was the worst. L2C-FNN also maintained its edge over other models, regardless of the number of observed timepoints, and regardless of the prediction horizon from 0 to 6 years into the future. ConclusionsL2C-FNN shows strong potential for both short-term and long-term dementia progression prediction. Pretrained ADNI models are available: https://github.com/ThomasYeoLab/CBIG/tree/master/stable_projects/predict_phenotypes/Zhang2025_L2CFNN.

Colonoscopy is a mainstay of colorectal cancer screening and has helped to lower cancer incidence and mortality. The resection of polyps during colonoscopy is critical for tissue diagnosis and prevention of colorectal cancer, albeit resulting in increased resource requirements and expense. Discarding resected benign polyps without sending for histopathological processing and confirmatory diagnosis, known as the resect and discard strategy, could enhance efficiency but is not commonly practiced due to endoscopists predominant preference for pathological confirmation. The inaccessibility of histopathology from unprocessed resected tissue hampers endoscopic decisions. We show that intraprocedural fibre-optic microscopy with ultraviolet-C surface excitation (FUSE) of polyps post-resection enables rapid diagnosis, potentially complementing endoscopic interpretation and incorporating pathologist oversight. In a clinical study of 28 patients, slide-free FUSE microscopy of freshly resected polyps yielded mucosal views that greatly magnified the surface patterns observed on endoscopy and revealed previously unavailable histopathological signatures. We term this new cross-specialty readout surface histology. In blinded interpretations of 42 polyps (19 training, 23 reading) by endoscopists and pathologists of varying experience, surface histology differentiated normal/benign, low-grade dysplasia, and high-grade dysplasia and cancer, with 100% performance in classifying high/low risk. This FUSE dataset was also successfully interpreted by foundation AI models pretrained on histopathology slides, illustrating a new potential for these models to not only expedite conventional pathology tasks but also autonomously provide instant expert feedback during procedures that typically lack pathologists. Surface histology readouts during colonoscopy promise to empower endoscopist decisions and broadly enhance confidence and participation in resect and discard. One Sentence SummaryRapid microscopy of resected polyps during colonoscopy yielded accurate diagnoses, promising to enhance colorectal screening.

BackgroundHepatic steatosis (HS) is a common cardiometabolic risk factor frequently present but under- diagnosed in patients with suspected or known coronary artery disease. We used artificial intelligence (AI) to automatically quantify hepatic tissue measures for identifying HS from CT attenuation correction (CTAC) scans during myocardial perfusion imaging (MPI) and evaluate their added prognostic value for all-cause mortality prediction. MethodsThis study included 27039 consecutive patients [57% male] with MPI scans from nine sites. We used an AI model to segment liver and spleen on low dose CTAC scans and quantify the liver measures, and the difference of liver minus spleen (LmS) measures. HS was defined as mean liver attenuation < 40 Hounsfield units (HU) or LmS attenuation < -10 HU. Additionally, we used seven sites to develop an AI liver risk index (LIRI) for comprehensive hepatic assessment by integrating the hepatic measures and two external sites to validate its improved prognostic value and generalizability for all-cause mortality prediction over HS. FindingsMedian (interquartile range [IQR]) age was 67 [58, 75] years and body mass index (BMI) was 29.5 [25.5, 34.7] kg/m2, with diabetes in 8950 (33%) patients. The algorithm identified HS in 6579 (24%) patients. During median [IQR] follow-up of 3.58 [1.86, 5.15] years, 4836 (18%) patients died. HS was associated with increased mortality risk overall (adjusted hazard ratio (HR): 1.14 [1.05, 1.24], p=0.0016) and in subpopulations. LIRI provided higher prognostic value than HS after adjustments overall (adjusted HR 1.5 [1.32, 1.69], p<0.0001 vs HR 1.16 [1.02, 1.31], p=0.0204) and in subpopulations. InterpretationsAI-based hepatic measures automatically identify HS from CTAC scans in patients undergoing MPI without additional radiation dose or physician interaction. Integrated liver assessment combining multiple hepatic imaging measures improved risk stratification for all-cause mortality. FundingNational Heart, Lung, and Blood Institute/National Institutes of Health. Research in context Evidence before this studyExisting studies show that fully automated hepatic quantification analysis from chest computed tomography (CT) scans is feasible. While hepatic measures show significant potential for improving risk stratification and patient management, CT attenuation correction (CTAC) scans from patients undergoing myocardial perfusion imaging (MPI) have rarely been utilized for concurrent and automated volumetric hepatic analysis beyond its current utilization for attenuation correction and coronary artery calcium burden assessment. We conducted a literature review on PubMed and Google Scholar on April 1st, 2025, using the following keywords: ("liver" OR "hepatic") AND ("quantification" OR "measure") AND ("risk stratification" OR "survival analysis" OR "prognosis" OR "prognostic prediction") AND ("CT" OR "computed tomography"). Previous studies have established approaches for the identification of hepatic steatosis (HS) and its prognostic value in various small- scale cohorts using either invasive biopsy or non-invasive imaging approaches. However, CT-based non- invasive imaging, existing research predominantly focuses on manual region-of-interest (ROI)-based hepatic quantification from selected CT slices or on identifying hepatic steatosis without comprehensive prognostic assessment in large-scale and multi-site cohorts, which hinders the association evaluation of hepatic steatosis for risk stratification in clinical routine with less precise estimates, weak statistical reliability, and limited subgroup analysis to assess bias effects. No existing studies investigated the prognostic value of hepatic steatosis measured in consecutive patients undergoing MPI. These patients usually present with multiple cardiovascular risk factors such as hypertension, dyslipidemia, diabetes and family history of coronary disease. Whether hepatic measures could provide added prognostic value over existing cardiometabolic factors is unknown. Furthermore, despite the diverse hepatic measures on CT in existing literature, integrated AI-based assessment has not been investigated before though it may improve the risk stratification further over HS. Lastly, previous research relied on dedicated CT scans performed for screening purposes. CTAC scans obtained routinely with MPI had never been utilized for automated HS detection and prognostic evaluation, despite being readily available at no additional cost or radiation exposure. Added value of this studyIn this multi-center (nine sites) international (three countries) study of 27039 consecutive patients undergoing myocardial perfusion imaging (MPI) with PET or SPECT, we used an innovative artificial intelligence (AI)- based approach for automatically segmenting the entire liver and spleen volumes from low-dose ungated CT attenuation correction (CTAC) scans acquired during MPI, followed by the identification of hepatic steatosis. We evaluated the added prognostic value of several key hepatic metrics--liver measures (mean attenuation, coefficient of variation (CoV), entropy, and standard deviation), and similar measures for the difference of liver minus spleen (LmS)--derived from volumetric quantification of CTAC scans with adjustment for existing clinical and MPI variables. A HS imaging criterion (HSIC: a patient has moderate or severe hepatic steatosis if the mean liver attenuation is < 40 Hounsfield unit (HU) or the difference of liver mean attenuation and spleen mean attenuation is < -10 HU) was used to detect HS. These hepatic metrics were assessed for their ability to predict all-cause mortality in a large-scale and multi-center patient cohort. Additionally, we developed and validated an eXtreme Gradient Boosting decision tree model for integrated liver assessment and risk stratification by combining the hepatic metrics with the demographic variables to derive a liver risk index (LIRI). Our results demonstrated strong associations between the hepatic metrics and all-cause mortality, even after adjustment for clinical variables, myocardial perfusion, and atherosclerosis biomarkers. Our results revealed significant differences in the association of HS with mortality in different sex, age, and race subpopulations. Similar differences were also observed in various chronic disease subpopulations such as obese and diabetic subpopulations. These results highlighted the modifying effects of various patient characteristics, partially accounting for the inconsistent association observed in existing studies. Compared with individual hepatic measures, LIRI showed significant improvement compared to HSIC-based HS in mortality prediction in external testing. All these demonstrate the feasibility of HS detection and integrated liver assessment from cardiac low-dose CT scans from MPI, which is also expected to apply for generic chest CT scans which have coverage of liver and spleen while prior studies used dedicated abdominal CT scans for such purposes. Implications of all the available evidenceRoutine point-of-care analysis of hepatic quantification can be seamlessly integrated into all MPI using CTAC scans to noninvasively identify HS at no additional cost or radiation exposure. The automatically derived hepatic metrics enhance risk stratification by providing additional prognostic value beyond existing clinical and imaging factors, and the LIRI enables comprehensive assessment of liver and further improves risk stratification and patient management.